Top-News

Ideaya Bioscience Aktie News

Aktie
WKN:  A2PJPB ISIN:  US45166A1025 US-Symbol:  IDYA Branche:  Biotechnologie Land:  USA
35,87 $
-0,14 $
-0,39%
30,806 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
2,42 Mrd. €
Streubesitz
-
KGV
-8,18
neu: Nachhaltigkeits-Score
22 %
Index-Zuordnung
-

Ideaya Bioscience News

28.03.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
26.03.25 - PR Newswire
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor PR Newswire
03.03.25 - PR Newswire
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-​Enabled Drug Discovery for Unprecedented First-​in-Class Oncology Targets PR Newswire
28.02.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
13.02.25 - PR Newswire
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update PR Newswire
13.02.25 - PR Newswire
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-​Deletion NSCLC PR Newswire
10.02.25 - PR Newswire
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer PR Newswire
31.01.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
27.01.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events PR Newswire
12.01.25 - PR Newswire
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance PR Newswire
29.12.24 - PR Newswire
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-​I-Payload ADC Targeting SCLC and NET Solid Tumors PR Newswire
27.12.24 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
17.12.24 - PR Newswire
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
IDEAYA Announces IDMC Recommendation of Move-​Forward Dose in Part 2a of Registration-​Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative ...
16.12.24 - PR Newswire
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-​in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung ...
11.12.24 - PR Newswire
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 PR Newswire
10.12.24 - PR Newswire
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
IDEAYA Announces First-​Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire
09.12.24 - PR Newswire
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-​in-Class MTA-​cooperative PRMT5 Inhibitor PR Newswire
06.12.24 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »